Neuropathic pain: Etiology, pathophysiology, mechanisms, and evaluations

Disease-a-Month

Volumn 60, Issue 1, 2014, Pages 6-47

  Jay, Gary W ^a   Barkin, Robert L ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANTIARRHYTHMIC AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIINFLAMMATORY AGENT; BACLOFEN; CAPSAICIN; CORTICOSTEROID; CREATININE; GLYCOPROTEIN GP 120; INTERLEUKIN 1; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; LIVER ENZYME; LOCAL ANESTHETIC AGENT; NERVE GROWTH FACTOR; OPIATE; POLYOL; PROTEIN KINASE C INHIBITOR; QUINOLONE DERIVATIVE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SUBSTANCE P; TAPENTADOL; TRAMADOL; TRICYCLIC ANTIDEPRESSANT AGENT; TUMOR NECROSIS FACTOR;

ABLATION THERAPY; ANXIETY; AUTONOMIC NEUROPATHY; BRAIN DEPTH STIMULATION; CANCER PAIN; CENTRAL POSTSTROKE PAIN; CLINICAL EXAMINATION; COMPLEX REGIONAL PAIN SYNDROME; DEPRESSION; DIABETIC NEUROPATHY; DRUG MECHANISM; ELECTRODIAGNOSIS; ELECTROMYOGRAPHY; GLIA; HIV ASSOCIATED NEUROPATHIC PAIN; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HYPERGLYCEMIA; LABORATORY DIAGNOSIS; LOW BACK PAIN; MEDICAL HISTORY; MONONEUROPATHY; NEUROPATHIC PAIN; NOCICEPTIVE PAIN; NON INSULIN DEPENDENT DIABETES MELLITUS; PAIN ASSESSMENT; PATHOPHYSIOLOGY; PATIENT SATISFACTION; PHANTOM PAIN; PHYSICAL EXAMINATION; POSTHERPETIC NEURALGIA; RADIODIAGNOSIS; RESTLESS LEGS SYNDROME; REVIEW; SIGNAL TRANSDUCTION; SMALL FIBER NEUROPATHY; SPINAL CORD STIMULATION; STIMULUS; TRANSCRANIAL MAGNETIC STIMULATION; TRANSCUTANEOUS NERVE STIMULATION; TRIGEMINUS NEURALGIA;

ANALGESICS; ANIMALS; HUMANS; NEURALGIA;

EID: 84893392747     PISSN: 00115029     EISSN: 15578194     Source Type: Journal    
DOI: 10.1016/j.disamonth.2013.12.001     Document Type: Review

References (342)

1. Fields H.L. Painful dysfunction of the nervous system. Pain 1987, 133-167. McGraw-Hill Book Company, New York, [chapter 6]. H.L. Fields (Ed.).
2. Bennett G.J. Neuropathic pain. Textbook of Pain 1994, 201-224. Churchill Livingstone, Edinburgh. 3rd ed. P.D. Wall, R. Melzack (Eds.).
3. Merskey H.H., Bogduk N. Classification of Chronic Pain: Descriptions of Chronic Pain Syndromes and Definitions of Pain Terms 1994, 212-213. IASP Press, Seattle, WA. 2nd ed.
4. Jay G.W. The autonomic nervous system. Pain Medicine: A Comprehensive Review 1996, 461-464. Mosby-Year Book, St. Louis, ([chapter 47]). P.P. Raj (Ed.).
5. Dworkin R.W., Backonja M., Rowbotham M.C., et al. Advances in neuropathic pain. Arch Neurol 2003, 60(11):1524-1534.
6. Scadding J.W. Neuropathic pain. Diseases of the Nervous system: Clinical Neurobiology 1992, 858-872. Harcourt Brace Jovanovich, WB Saunders Company, Philadelphia. 2nd ed. A.K. Asbury, G.M. McKhann, W.I. McDonald (Eds.).
7. Kennedy L.D., Longmire D.R. Medical/laboratory evaluation of pain patients. Pain Digest 1992, 1(4):306-312.
8. Longmire D.R. Evaluation of the pain patient. Pain Medicine, a Comprehensive Review 1996, 26-34. [chapter 3]. P.P. Raj (Ed.).
9. Kennedy L.D. Laboratory investigations. Pain Medicine, a Comprehensive Review 1996, 47-54. [chapter 5]. P.P. Raj (Ed.).
10. Devor M. The pathophysiology of damaged peripheral nerves. Textbook of Pain 1994, 79-100. Churchill Livingstone, Edinburgh. 3rd ed. P.D. Wall, R. Melzack (Eds.).
11. Devor M. Neurobiological basis for selectivity of sodium channel blockers in neuropathic pain. Pain Forum 1995, 4:83-86.
12. Tanelian D.L., Victory R.A. Sodium channel-blocking agents. Their use in neuropathic pain conditions. Pain Forum 1995, 4:75-80.
13. Chaplan S.R. Neuropathic pain: role of voltage-dependent calcium channels. Reg Anesth Pain Med 2000, 25(3):283-285.
14. Novakovic S.D., Tzoumaka E., McGivern J.G., et al. Distribution of the tetrodotoxin-resistant sodium channel PN3 in rat sensory neurons in normal and neuropathic conditions. J Neurosci 1998, 18(6):2174-2187.
15. Mersky H., Bogduk N. Classification of Chronic Pain 1994, IASP Press, Seattle, WA. 2nd ed.
16. Woolf C.J., Salter M.W. Neuronal plasticity: increasing the gain in pain. Science 2000, 288(5472):1765-1769.
17. Klein T., Magerl W., Rolke R., Treede R.D. Human surrogate models of neuropathic pain. Pain 2005, 115(3):227-233.
18. Thomas P.K, Tomlinson Diabetic and hypoglycemic neuropathy. Peripheral Neuropathy 1993, 1219-1250. WB Saunders, Philadelphia. P.J. Dyck, P.K. Thomas (Eds.).
19. Ziegler D., Gries F.A., Spuler M., Lessmann F. The epidemiology of diabetic neuropathy. DiaCAN Multicenter Study Group. Diabet Med 1993, 10(suppl 2):82S-86S.
20. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993, 329(14):977-986. The DCCT Research Group.
21. Report and recommendations of the San Antonio conference on diabetic neuropathy. Consensus statement. Diabetes 1988, 37(7):1000-1004.
22. Thomas P.K. Classification, differential diagnosis, and staging of diabetic peripheral neuropathy. Diabetes 1997, 46(suppl 2):S54-S57.
23. Boulton A.J.M., Ward J.D. Diabetic neuropathies and pain. Clin Endocrinol Metab 1986, 15(4):917-931.
24. Bhadada S.K., Sahay R.K., Jyotsna V.P., Agrawal J.K. Diabetic neuropathy: current concepts. J Indian Acad Clin Med 2001, 2(4):305-316.
25. Archer A.G., Watkins P.J., Thomas P.K., Sharma A.K., Payan J. The natural history of acute painful neuropathy in diabetes mellitus. J Neurol Neurosurg Psychiatry 1983, 46(6):491-499.
26. Soliman E. Gellido. Diabetic Neuropathy. 〈〉; 2004. http://eMedicine.com.
27. Krendel D.A., Zacharias A., Younger D.S. Autoimmune diabetic neuropathy. Neurol Clin 1997, 15(4):959-971.
28. Dyck P.J., Norell J.E., Dyck P.J. Non-diabetic lumbosacral radiculoplexus neuropathy: natural history, outcome and comparison with the diabetic variety. Brain 2001, 124(Pt 6):1197-1207.
29. Dyck P.J., Windebank A.J. Diabetic and nondiabetic lumbosacral radiculoplexus neuropathies: new insights into pathophysiology and treatment. Muscle Nerve 2002, 25(4):477-491.
30. Kazem S.S., Behzad D. Role of blink reflex in diagnosis of subclinical cranial neuropathy in diabetic mellitus type II. Electromyogr Clin Neurophysiol 2005, 45(5):299-303.
31. Janaky M., Fulop Z., Palffy A., Benedek K., Benekek G. Non-arteritic ischaemic optic neuropathy (NAION) in patients under 50 years of age. Acta Ophthalmol Scand 2005, 83(4):499-503.
32. Kao H.J., Chang Y.Y., Lan M.Y., Kao Y.F., Wu H.S., Liu J.S. Diabetic inferior division palsy of the oculomotor nerve. Acta Neurol Taiwan 2005, 14(2):79-83.
33. Ramunni A., Giancipoli G., Guerriero S., et al. LDL-apheresis accelerates the recovery of nonarteritic acute anterior ischemic optic neuropathy. Ther Apher Dial 2005, 9(1):53-58.
34. Ellenberg M. Diabetic truncal mononeuropathy-a new clinical syndrome. Diabetes Care 1978, 1(1):10-13.
35. Massey E.W. Diabetic truncal mononeuropathy: electromyographic evaluation. Acta Diabetol Lat 1980, 17(3-4):269-272.
36. Brooks PV. Mononeuritis Multiplex. 〈〉; 2002. http://eMedicine.com.
37. Toyry J.P., Niskaner L.K., Mantysaari M.J., et al. Occurrence predictors and clinical significance of autonomic neuropathy in NIDDM: ten years follow up from diagnosis. Diabetes 1996, 45(3):308-315.
38. Vinik A.I., Erbas T. Recognizing and treating diabetic autonomic neuropathy. Clev Clinic J Med 2001, 68(11):928-944.
39. Vinik A.I., Freeman R., Tomris E. Diabetic autonomic neuropathy. Semin Neurol 2003, 23(4):365-372.
40. Ziegler D., Gries F.A., Spuler M., Lessmann F. Diabetic Cardiovascular Autonomic Neuropathy Multicenter Study Group: the epidemiology of diabetic neuropathy. J Diabetes Complications 1992, 6(1):49-57.
41. Sampson M.J., Wilson S., Karagiannis P., Edmonds M., Watkins P.J. Progression of diabetic autonomic neuropathy over a decade in insulin-dependent diabetics. Quart J Med 1990, 75(278):635-646.
42. Kocer A., Zekeriya A., Maden E., Tasci A. Orthostatic hypotension and heart rate variability as indicators of cardiac autonomic neuropathy in diabetes mellitus. Eur J Gen Med 2005, 2(1):5-9.
43. Lee S.P., Yeoh L., Harris N.D., et al. Influence of autonomic neuropathy on QTc interval lengthening during hypoglycemia in type 1 diabetes. Diabetes 2004, 53(6):1535-1542.
44. Sivieri R., Veglio M., Chinaglia A., et al. Prevalence of QT prolongation in a type 1 diabetic population and its association with autonomic neuropathy: the neuropathy study group of the Italian society for the study of diabetes. Diabet Med 1993, 10(10):920-924.
45. Ewing D.J., Neilson JM. QT interval length and diabetic autonomic neuropathy. Diabet Med 1990, 7(1):23-26.
46. Weston P.J., James M.A., Panerai R., et al. Abnormal baroreceptor-cardiac reflex sensitivity is not detected by conventional tests of autonomic function in patients with insulin-dependent diabetes mellitus. Clin Sci 1996, 91(1):59-64.
47. Ziegler D. Diabetic cardiovascular autonomic neuropathy: prognosis, diagnosis and treatment. Diabetes Metab Rev 1994, 10(4):339-383.
48. Malpas S.C., Maling T.J. Heart-rate variability and cardiac autonomic function in diabetes. Diabetes 1990, 39(10):1177-1181.
49. Coumel P., Johnson N., Extramiana F., et al. Electrocardiography changes and rhythm problems in the diabetic. Arch Mal Coeru Vaiss 2000, 93(Spec No 4):59-66. [Abstract].
50. Taskiran M., Fritz-Hansen T., Rasmussen B., et al. Decreased myocardial perfusion reserve in diabetic autonomic neuropathy. Diabetes 2002, 51(11):3306-3310.
51. Ewing D.J., Boland O., Neilson J.M., et al. Autonomic neuropathy, QT interval lengthening, and unexpected deaths in male diabetic patients. Diabetologia 1991, 34(3):182-185.
52. Weston P.J., Gill G.V. Is undetected autonomic dysfunction responsible for sudden death in type 1 diabetes mellitusα The 'dead in bed' syndrome revisited. Diabet Med 1999, 16(8):626-631.
53. Farrell T.G., Odemuyiwa O., Bashir Y., et al. Prognostic value of baroreflex sensitivity testing after acute myocardial infarction. Br Heart J 1992, 67(2):129-137.
54. La Rovere M.T., Bigger J.T., Marcus F.I., et al. Baroreflex sensitivity and heart-rate variability in prediction of total cardiac mortality after myocardial infarction. Lancet 1998, 351(9101):478-484.
55. Aring A.M., Jones D.E., Falko J.M. Evaluation and prevention of diabetic neuropathy. Am Fam Physician 2005, 71(2131-8):2129-2130.
56. Consensus development conference on the diagnosis of coronary heart disease in people with diabetes: 10-11 February 1998, Miami, Florida. American Diabetes Association. Diabetes Care 1998, 21(9):1551-1559.
57. Lagi A., Cipriani M., Paggetti C., et al. Power spectrum analysis of heart rate variations in the early detection of diabetic autonomic neuropathy. Clin Auton Res 1994, 4(5):245-248.
58. Vinik A., Mehrabyan A., Colen L., Boulton A. Focal entrapment neuropathies in diabetes. Diabetes Care 2004, 27(7):1783-1788.
59. The effect of intensive diabetes therapy on the development and progression of neuropathy. Ann Intern Med 1995, 122(8):651-688. DCCT Research Group.
60. Kelkar P. Diabetic neuropathy. Semin Neurol 2005, 25(2):168-173.
61. Oates P.J. Polyol pathway and diabetic peripheral neuropathy. Int Rev Neurobiol 2002, 50:325-392.
62. Yamagishi S., Imaizumi T. Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy. Curr Pharm Des 2005, 11(18):2279-2299.
63. Ahmad F.K., He Z., King G.L. Molecular targets of diabetic cardiovascular complications. Curr Drug Targets 2005, 6(4):487-494.
64. Defraigne J.O. A central pathological mechanism explaining diabetic complicationsα. Rev Med Liege 2005, 60(5-6):472-478.
65. Chung S.S., Chung S.K. Aldose reductase in diabetic microvascular complications. Curr Drug Targets 2005, 6(4):475-486.
66. Cameron N.E., Eaton S.E., Cotter M.A., Tesfaye S. Vascular factors and metabolic interactions in the pathogenesis of diabetic neuropathy. Diabetologia 2001, 44(11):1973-1988.
67. Craner J.M., Klein J.P., Renganathan M., et al. Changes of sodium channel expression in experimental painful diabetic neuropathy. Ann Neurol 2002, 52(6):786-792.
68. Hall K.E., Liu J., Sima A.A., Wiley J.W. Impaired G-protein function contributes to increased calcium currents in rats with diabetic neuropathy. J Neurophysiol 2001, 86(2):760-770.
69. Gingliano D., Ceriello A., Pawlisso G. Oxidative stress and diabetic vascular complications. Diabetes Care 1996, 19(3):257-267.
70. Inoguchi T., Sonta T., Tsubouchi H., et al. Protein kinase C-dependent increase in reactive oxygen species (ROS) production in vascular tissues of diabetes: role of vascular NAD(P)H oxidase. J Am Soc Nephrol 2003, 14(8 Suppl 3):S227-S232.
71. Idris I., Gray S., Donnely R. Protein kinase C activation: isozyme-specific effects on metabolism and cardiovascular complications in diabetes. Diabetologia 2001, 44(6):657-658.
72. Qu X., Seale J.P., Donnely R. Tissue and isoform-selective activation of protein kinase C in insulin-resistant obese Zucker rats-effects of feeding. J Endocrinol 1999, 162(2):207-214.
73. Cameron N.E., Cotter M.A., Horrobin D.H., Tritschler H.J. Effects of alpha-lipoic acid on neurovascular function in diabetic rats: interaction with essential fatty acids. Diabetologia 1998, 41(4):390-399.
74. Jamal G.A. The use of gamma linolenic acid in the prevention and treatment of diabetic neuropathy. Diabet Med 1994, 11(2):145-149.
75. Faradji V., Sotelo J. Low serum levels of nerve growth factor in diabetic neuropathy. Acta Neurol Scand 1990, 81(5):402-413.
76. Apfel S.C., Kessler J.A., Adornato B.T., et al. Recombinant human nerve growth factor in the treatment of diabetic polyneuropathy. NGF Study Group. Neurology 1998, 51(3):695-702.
77. Fink E., Oaklander A.L. Small-fiber neuropathy: answering the burning questions. Sci Aging Knowledge Environ 2006, 6:7.
78. Lacomis D. Small-fiber neuropathy. Muscle Nerve 2002, 26(2):173-188.
79. Hoitsma E., Reulen J.P., de Baets M, et al. Small fiber neuropathy: a common and important clinical disorder. J Neurol Sci 2004, 227(1):119-130.
80. Singleton J.R. Evaluation and treatment of painful peripheral polyneuropathy. Semin Neurol 2005, 25(2):185-195.
81. Polydefkis M., Allen R.P., Hauer P., et al. Subclinical sensory neuropathy in late-onset restless-legs syndrome. Neurology 2000, 55(8):1115-1121.
82. Koves P., Szakacs Z. Pathophysiology of restless leg syndrome and periodic leg movement disorder in view of the latest research findings. Ideggyogy Sz 2005, 58(5-6):148-163. [Abstract].
83. Gemignani F., Brindani F., Negrotti A., et al. Restless legs syndrome and polyneuropathy. Mov Disord 2006, [Epub ahead of print].
84. Stewart J.D., Low P.A., Fealey R.D. Distal small-fiber neuropathy: results of tests of sweating and autonomic cardiovascular reflexes. Muscle Nerve 1992, 15(6):661-665.
85. Novak V., Friemer M.L., Kissel J.T., et al. Autonomic impairment in painful neuropathy. Neurology 2001, 56(7):861-868.
86. Coluzzi F., Mattia C. Mechanism-based treatment in chronic neuropathic pain: the role of antidepressants. Curr Pharm Design 2005, 11(23):2945-2960.
87. Mullins C.R., Wild T.L. Pain management in a long-term care facility: compliance with JCAHO standards. J Pain Palliat Care Pharmacother 2003, 17(2):63-70.
88. Oh S.J., Melo A.C., Lee D.K., et al. Large-fiber neuropathy in distal sensory neuropathy with normal routine nerve conduction. Neurology 2001, 56(11):1570-1572.
89. Jamal G.A., Hansen S., Weir A.I., et al. The neurophysiologic investigation of small fiber neuropathies. Muscle Nerve 1987, 10(6):537-545.
90. Longmire D.R. An electrophysiological approach to the evaluation of regional sympathetic dysfunction: a proposed classification. Pain Physician 2006, 9(1):69-82.
91. Cheliout-Heraut F., Zrek N., Khemliche H., et al. Exploration of small fibers for testing diabetic neuropathies. Joint Bone Spine 2005, 72(5):412-415.
92. Periquet M.I., Novak V., Collins M.P., et al. Painful sensory neuropathy: prospective evaluation using skin biopsy. Neurology 1999, 53(8):1641-1647.
93. Low V.A., Sandroni P., Fealey R.D., Low P.A. Detection of small-fiber neuropathy by sudomotor testing. Muscle Nerve 2006, 34(1):57-61.
94. Thompson R.J., Doran J.F., Jackson P., et al. PGP 9.5-a new marker for vertebrate neurons and neuroendocrine cells. Brain Res 1983, 278(1-2):224-228.
95. Wendelschafer-Crabb G., Kennedy W.R., Walk D. Morphological features of nerves in skin biopsies. J Neurol Sci 2006, 242(1-2):15-21.
96. Smith A.G., Howard J.R., Kroll R., et al. The reliability of skin biopsy with measurement of intraepidermal nerve fiber density. J Neurol Sci 2005, 228(1):65-69.
97. Caselli A., Spallone V., Marfia G.A., et al. Validation of the nerve axon reflex for the assessment of small nerve fiber dysfunction. J Neurol Neurosurg Psychiatry 2006, 77(8):927-932.
98. Sorensen L., Molyneaux L., Yue D.K. The level of small nerve fiber dysfunction does not predict pain in diabetic neuropathy: a study using quantitative sensory testing. Clin J Pain 2006, 22(3):261-265.
99. Sorensen L., Molyneaux L., Yue D.K. The relationship among pain, sensory loss, and small nerve fibers in diabetes. Diabetes Care 2006, 29(4):883-887.
100. Smith G., Robinson S. Idiopathic neuropathy, prediabetes and the metabolic syndrome. J Neurol Sci 2006, 242(1-2):9-14.
101. Hoffman-Snyder C., Smith B.E., Ross M.A., et al. Value of the oral glucose tolerance test in the evaluation of chronic idiopathic axonal polyneuropathy. Arch Neurol 2006, 63(8):1075-1079.
102. Zambelis T., Karandreas N., Tzavellas E., et al. Large and small fiber neuropathy in chronic alcohol-dependent subjects. J Peripher Nerv Syst 2005, 10(4):375-381.
103. Herrmann D.N., McDermott M.P., Sowden J.E., et al. Is skin biopsy a predictor of transition to symptomatic HIV neuropathyα A longitudinal study. Neurology 2006, 66(6):857-861.
104. Brannagan T.H., Hays A.P., Chin S.S., et al. Small-fiber neuropathy/neuronopathy associated with celiac disease: skin biopsy findings. Arch Neurol 2005, 62(10):1574-1578.
105. Chin R.I., Latov N. Peripheral neuropathy and celiac disease. Curr Treat Options Neurol 2005, 7(1):43-48.
106. Chai J., Herrmann D.N., Stanton M., et al. Painful small-fiber neuropathy in Sjogren syndrome. Neurology 2005, 65(6):925-927.
107. Goransson L.G., Ab Tjensvoll, Herigstad A., et al. Small diameter nerve fiber neuropathy in systemic lupus erythematosus. Arch Neurol 2006, 63(3):401-404.
108. Lee J.E., Shun C.T., Hsieh S.C., Hsieh S.T. Skin denervation in vasculitic neuropathy. Arch Neurol 2005, 62(10):1570-1573.
109. Kararizou E., Davaki P., Karandreas N., et al. Nonsystemic vasculitic neuropathy: a clinicopathological study of 22 cases. J Rheumatol 2005, 32(5):853-858.
110. Dabby R., Gilad R., Dadeh M., et al. Acute steroid responsive small-fiber sensory neuropathy: a new entityα. J Peripher Nerv Syst 2006, 11(1):47-52.
111. Estanislao L., Carter K., McAthur J., et al. A randomized controlled trial of 5% lidocaine gel for HIV-associated distal symmetric polyneuropathy. J Acquir Immune Defic Syndr 2004, 37(5):1584-1586.
112. Verma S., Estanislao L., Simpson D. HIV-Associated neuropathic pain: epidemiology, pathophysiology and management. CNS Drugs 2005, 19(4):325-334.
113. Pardo C.A., McArthur J.C., Griffin J.W. HIV neuropathy: insights in the pathology of HIV peripheral nerve disease. J Peripher Nerv Syst 2001, 6(1):21-27.
114. Herzberg U., Sagen J. Peripheral nerve exposure to HIV viral envelope protein gp120 induces neuropathic pain and spinal gliosis. J Neuroimmunol 2001, 116(116):29-39.
115. Apostolski S., McAlarney T., Quattrini A., et al. The gp120 glycoprotein of human immunodeficiency virus type 1 binds to sensory ganglion neurons. Ann Neurol 1993, 34(6):855-863.
116. Oh S.B., Tran P.B., Gillard S.E., et al. Chemokines and glycoprotein in 120 produce pain hypersensitivity by directly exciting primary nociceptive neurons. J Neurosci 2001, 21(14):5027-5035.
117. Imam I. The neurology of HIV infection-a review of the literature. Niger J Med 2005, 14(2):121-131.
118. Verma S., Micsa E., Estanislao L. Neuromuscular complications in HIV. Curr Neurol Neurosci Rep 2004, 4(1):62-67.
119. Verma S., Estanislao L., Mintz L., Simpson D. Controlling neuropathic pain in HIV. Curr HIV/AIDS Rep 2004, 1(3):136-141.
120. Power C., Gill M.J., Johnson R.T. Progress in clinical neurosciences. The neuropathogenesis of HIV infection: host-virus interaction and the impact of therapy. Can J Neurol Sci 2002, 29(1):19-32.
121. Breen E.C. Pro- and anti-inflammatory cytokines in human immunodeficiency virus infection and acquired immunodeficiency syndrome. Pharmacol Ther 2002, 95(3):295-304.
122. Youle M. HIV-associated antiretroviral toxic neuropathy (ATN): a review of recent advances in pathophysiology and treatment. Antivir Ther 2005, 10(suppl 2):M125-M129.
123. Scutellari P.N., RIzzati R., Antinolfi G., et al. The value of computed tomography in the diagnosis of low back pain. A review of 2,012 cases. Minerva Med 2005, 96(1):41-59.
124. Brisby H. Pathology and possible mechanisms of nervous system response to disc degeneration. J Bone Joint Surg Am 2006, 88(suppl 2):68-71.
125. Audette J.F., Emenike E., Meleger A.L. Neuropathic low back pain. Curr Pain Headache Rep 2005, 9(3):168-177.
126. Freemont A.J., Peacock T.E., Goupille P., et al. Nerve ingrowth into diseased intervertebral disc in chronic back pain. Lancet 1997, 350(9072):178-181.
127. Coppes M.H., Marani E., Thomeer R., Groen G.J. Innervation of "painful" lumbar discs. Spine 1997, 22(20):2342-2349.
128. Baron R., Binder A. How neuropathic is sciaticaα The mixed pain concept. Orthopade 2004, 33(5):568-575.
129. Kaki A.M., El Yaski A.Z., Youseif E. Identifying neuropathic pain among patients with chronic low-back pain: use of the Leeds Assessment of Neuropathic Symptoms and Signs pain scale. Reg Anesth Pain Med 2005, 30(5):422-428.
130. Bennett M.I., SMither B.H., Torrance N., Lee A.J. Can pain be more or less neuropathicα Comparison of symptom assessment tools with ratings of certainty by clinicians. Pain 2006, 122(3):289-294.
131. Khoromi S., Patsalides A., Parada S., et al. Topiramate in chronic lumbar radicular pain. J Pain 2005, 6(12):829-836.
132. Katz J., Pennella O., Vaughan J., Hetzel R.D., et al. A randomized, placebo-controlled trial of bupropion sustained release in chronic low back pain. J Pain 2005, 6(10):656-661.
133. Dejerine J., Roussy G. Le syndrome thalamique. Rev Neurol 1906, 14:521-532.
134. Greiff N. Zur localization der hemichorea. Archiv fur der Psychologie and Nervenkrankheiten 1883, 14:598.
135. Bowsher D. Sensory consequences of stroke. Lancet 1993, 341(8388):156. [letter].
136. Andersen G., Vestergaard K., Ingeman-Neilsen M., Jensen T.S. The incidence of central post-stroke pain. Pain 1995, 61(2):187-193.
137. MacGowan D.J., Janal M.N., Clark W.C., et al. Central poststroke pain and Wallenberg's lateral medullary infarction: frequency, character and determinants in 63 patients. Neurology 1997, 49(1):120-125.
138. Bowsher D. The management of central post-stroke pain (Review). Postgrad Med J 1995, 71(840):598-604.
139. Leijon G., Boivie J., Johansson I. Central post-stroke pain-neurological symptoms and pain characteristics. Pain 1989, 36(1):13-25.
140. Holmgren H., Leijon G., Boivie J., et al. Central post-stroke pain-somatosensory evoked potentials in relation to location of the lesion and sensory signs. Pain 1990, 40(1):43-52.
141. Wessel K., Vieregge P., Kessler C., Kompf D. Thalamic stroke: correlation of clinical symptoms, somatosensory evoked potentials and CT findings. Acta Neurol Scand 1994, 90(3):167-173.
142. Bowsher D. Central pain: clinical and physiological characteristics. J Neurol Neurosurg Psychiatry 1996, 61(1):62-69.
143. Mersky H.H., Lindblom U., Mumford J.M., Nathan P.W. Pain terms: a current note with definitions and notes on usage. Pain Suppl 1986, 3:216-221.
144. Boivie J. Central pain. Textbook of Pain 1994, 871-902. Churchill Livingstone, New York. 3rd ed. P.D. Wall, R. Melzack (Eds.).
145. Jensen T.S., Lenz F.A. Central post-stroke pain: a challenge for the scientist and the clinician. Pain 1995, 61(2):62-69. [editorial].
146. Lenz F.A. Ascending modulation of thalamic function and pain; experimental and clinical data. Advances in pain research and therapy 1992, 177-196. Raven, New York. F. Sicuteri (Ed.).
147. Jones E.G. Thalamus and pain. AAPS J 1992, 1:58-61.
148. Boivie J. Hyperalgesia and allodynia in patients with CNS lesions. Hyperalgesia and Allodynia 1992, 363-373. Raven, New York. W.D.J. Willis (Ed.).
149. Sandy R. Spontaneous pain, hyperpathia and wasting of the hand due to parietal lobe haemorrhage. Eur Neurol 1985, 24(1):1-3.
150. Riddoch G. The clinical features of central pain. Lancet 1938, 234(1093-1098):1205-1209. (1150-1056).
151. Gorecki J., Hirayama T., Dostrovsky J.O., et al. Thalamic stimulation and recording in patients with deafferentation and central pain. Stereotact Funct Neurosurg 1989, 52(2-4):120-126.
152. Yamashiro K., Iwayama K., Kurihara M., et al. Neurones with epileptiform discharge in the central nervous system and chronic pain: experimental and clinical investigations. Acta Neurochir Suppl 1991, 52:130-132.
153. Hirato M., Watanabe K., Takahashi A., et al. Pathophysiology of central (thalamic) pain: combined change of sensory thalamus with cerebral cortex around central sulcus. Stereotact Funct Neurosurg 1994, 62(1-4):300-303.
154. Leijon G., Boivie J. Central post-stroke pain-a controlled trial of amitriptyline and carbamazepine. Pain 1989, 36(1):27-36.
155. Davidoff G., Guarrachini M., Roth E., Sliwa J., Yarkony G. Trazodone hydrochloride in the treatment of dysesthetic pain in traumatic myelopathy: a randomized, double blind, placebo-controlled study. Pain 1987, 29(2):151-161.
156. Ekbom K. Tegretol, a new therapy of tabetic lightning pains. Acta Med Scand 1966, 179(2):251-252.
157. Swerdlow M. Anticonvulsants in the therapy of neuralgic pain. Pain Clin 1986, 1:9-19.
158. Kastrup J., Petersen P., Dejgard A., Angelo H.R., Hilsted J. Intravenous lidocaine infusion-a new treatment of chronic painful diabetic neuropathyα. Pain 1987, 28(1):69-75.
159. Awerbuch A. Treatment of thalamic pain syndrome with Mexilitene. Ann Neurol 1990, 28:233.
160. Portenoy R.K., Foley K.M., Inturrisi C.E. The nature of opioid responsive-ness and its implications for neuropathic pain: new hypotheses derived from studies of opioid infusions. Pain 1990, 43(3):272-286.
161. Leijon G., Boivie J. Treatment of neurogenic pain with antidepressants. Nord J Psychiatry 1989, 43(suppl 20):83-87.
162. Leijon G., Boivie J. Central post-stroke pain-the effect of high and low frequency TENS. Pain 1989, 38(2):187-191.
163. Siegfried J. Long term results of electrical stimulation in the treatment of pain my means of implanted electrodes. Pain Therapy 1983, 463-475. Elsevier, Amsterdam. C. Rizzi, T.A. Visentin (Eds.).
164. Tasker R., de Carvalho G., Dostrovsky J.O. The history of central pain syndromes, with observations concerning pathophysiology and treatment. Pain and Central Nervos Disease: The Central Pain Syndromes 1991, 31-58. Raven, New York. ed. K.L. Casey (Ed.).
165. Siegfried J., Demierre B. Thalamic electrostimulation in the treatment of thalamic pain syndrome. Pain 1984, suppl 2:116.
166. Tasker R. Pain resulting from central nervous system pathology (central pain). The Management of Pain 1990, 264-280. Lea and Febiger, Philadelphia. J.J. Bonica (Ed.).
167. Edgar R.E., Best L.G., Quail P.A., Obert A.D. Computer-assisted DREZ microcoagulation: posttramatic spinal deafferentation pain. J Spinal Dis 1993, 6(1):48-56.
168. Nashold B.S., Bullitt E. Dorsal root entry zone lesions to control central pain in paraplegics. J Neurosurg 1981, 55(3):414-419.
169. Bowsher D., Nurmikko T. Central post-stroke pain drug treatment options. Dis Manag 1996, 5:160-165.
170. Loh L., Nathan P.W., Schott G.D. Pain due to lesions of central nervous system removed by sympathetic block. Br Med J 1981, 282(6269):1026-1028.
171. McLachlan E.M., Janig W., Devor M., Michaelis M. Peripheral nerve injury triggers noradrenergic sprouting within dorsal root ganglia. Nature 1993, 363(6429):543-546.
172. Woolf C.J., Mannion R.J. Neuropathic pain: aetiology, symptoms, mechanisms, and management. Lancet 1999, 353(9168):1959-1964.
173. Woolf C.J., Shortland P., Coggeshall R.E. Peripheral nerve injury triggers central sprouting of myelinated afferents. Nature 1992, 355(6355):75-77.
174. Ossipov M.H., Lai J., Malan T.P., Porreca F. Spinal and supraspinal mechanisms of neuropathic pain. Ann N Y Acad Sci 2000, 909:12-24.
175. Tenser RB, Dworkin RH. Herpes zoster and the prevention of postherpetic neuralgia. Neurology 2005, 65(3):349-350. [editorial].
176. Watson C.P. Postherpetic neuralgia: the importance of preventing this intractable end-stage disorder. J Infect Dis 1998, 178(Suppl 1):S91-S94.
177. Dubinsky R.M., Kabbani H., El-Chami Z., et al. Practice parameter: treatment of postherpetic neuralgia. An evidence-based report of the quality standards subcommittee of the American Academy of Neurology. Neurology 2004, 63(6):959-965.
178. de Moragas J.M., Kierland R.R. The outcome of patients with herpes zoster. Arch Dermatol 1957, 75(2):193-196.
179. Watson C.P., Evans R.J., Watt V.R., Birkett N. Post-herpetic neuralgia: 208 cases. Pain 1988, 35(3):289-297.
180. Kurtzke J.F. Neuroepidemiology. Ann Neurol 1984, 16(3):265-277.
181. Donahue J.G., Choo P.W., Manson J.E., Platt R. The incidence of herpes zoster. Arch Intern Med 1995, 155(15):1605-1609.
182. Helgeson S., Petursson G., Gudmundsson S., Sigurdson J.A. Prevalence of postherpetic neuralgia after a first episode of herpes zoster: prospective study with long term follow-up. Br Med J 2000, 321(7264):794-796.
183. Hope-Simpson R.E. The nature of herpes zoster: a long-term study and a new hypothesis. Proc R Soc Med 1965, 58:9-20.
184. Beydoun SR. Postherpetic neuralgia-a model of neuropathic pain: overview of the pathogenesis and current therapeutic options. CME Article. 〈〉. http://www.pain.com.
185. Rowbotham MC, Petersen KL, Fields HL. Is post-herpetic neuralgia more than one disorderα Technical corner from IASP newsletter. 〈〉; 1999. http://www.iasp-pain.org/TC99Fall.html.
186. Kost R.G., Straus S.E. Postherpetic neuralgia- pathogenesis, treatment and prevention. N Engl J Med 1996, 335(1):32-42.
187. Bowsher D. The effects of pre-emptive treatment of postherpetic neuralgia with amitriptyline: a randomized, double blind, placebo controlled trial. J Pain Symptom Manage 1997, 13(6):327-331.
188. Watson C.P., Chipman M., Reed K., Evans R.J., Birkett N. Amitriptyline versus maprotiline in postherpetic neuralgia: a randomized, double-blind crossover trial. Pain 1992, 48(1):29-36.
189. Raja S.N., Haythornthwaite J.A., Pappagallo M., et al. Opioids versus antidepressants in postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology 2002, 59(7):1015-1021.
190. Gnann J.W.J., Whitely RJ. Clinical practice. Herpes zoster. N Engl J Med 2002, 347(5):340-346.
191. Watson C.P., Babul N. Efficacy of oxycodone in neuropathic pain: a randomized trial in postherpetic neuralgia. Neurology 1998, 50(6):1837-1841.
192. Rowbotham M., Harden N., Stacey B., et al. Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial. J Am Med Assoc 1998, 280L(21):1837-1842.
193. Rice A.C.S., Maton S. Gabapentin in postherpetic neuralgia: a randomized, double blind, placebo controlled study. Pain 2001, 94(2):215-224.
194. Gee N.S., Brown J.P., Dissanayake V.U., et al. The novel anticonvulsant drug, gabapentin (Neurontin) binds to the alpha2delta subunit of a calcium channel. J Biol Chem 1996, 271(10):5768-5776.
195. Dworkin R.H., Corbin A.E., Young J.P., et al. Pregabalin for the treatment of postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology 2003, 60(8):1274-1283.
196. Pappagallo M., Campbell J.N. Chronic opioid therapy as alternative treatment for post-herpetic neuralgia. Ann Neurol 1994, 35(suppl):S54-S56.
197. Rowbotham M.C., Fields H.L. Topical lidocaine reduces pain in post-herpetic neuralgia. Pain 1989, 38(3):29-301.
198. Rowbotham M.C., Davies P.S., Verkempinck C., Galer B.S. Lidocaine patch: double-blind, controlled study of a new treatment method for post-herpetic neuralgia. Pain 1996, 65(1):39-44.
199. Watson C.P., Tyler K.L., Bickers D.R., et al. A randomized vehicle-controlled trial of topical capsaicin in the treatment of postherpetic neuralgia. Clin Ther 1993, 15(3):510-526.
200. Don P.C. Topical capsaicin for treatment of neuralgia associated with herpes zoster injection. J Am Acad Dermatol 1988, 18(5 Pt. 1):1135-1136.
201. Bernstein J.E., Korman N.J., Bickers D.R., et al. Topical capsaicin treatment of chronic postherpetic neuralgia. J Am Acad Dermatol 1989, 21(2 Pt.1):265-270.
202. Kikuchi A., Kotani N., Sato T., et al. Comparative therapeutic evaluation of intrathecal versus epidural methylpresnisolone for long-term analgesia in patients with intractable postherpetic neuralgia. Reg Anesth Pain Med 1999, 24(4):287-293.
203. Kotani N., Kushikata T., Hashimoto H., et al. Intrathecal methylprednisolone for intractable postherpetic neuralgia. N Engl J Med 2000, 343(21):1514-1519.
204. Klepstad P., Borchgrevink P.C. Four years' treatment with ketamine and a trial of dextromethorphan in a patient with severe post-herpetic neuralgia. Acta Anaesthesiol Scand 1997, 41(3):422-426.
205. Carson M.J., Reilly C.R., Sutcliffe J.G., Lo D. Mature microglia resemble immature antigen-presenting cells. Glia 1998, 22(1):72-85.
206. Bartlett P.F. Pluripotential hemopoetic stem cells in adult mouse brain. Proc Natl Acad Sci U S A 1982, 79(8):2722-2725.
207. Verge G.M., Milligan E.D., Maier S.F., et al. Fractalkine (CX3CL1) and fractalkine receptor (CX3CR1) distribution in spinal cord and dorsal root ganglia under basal and neuropathic conditions. Eur J Neurosci 2004, 20(5):1150-1160.
208. Watkins L.R., Milligan E.D., Maier S.F. Glial activation: a driving force for pathological pain. Trends Neurosci 2001, 24(8):450-455.
209. Watkins L.R., Maier S.F. Glia: a novel drug discovery target for clinical pain. Nat Rev Drug Disc 2003, 2(12):973-985.
210. Wieseler F.J., Maier S.F., Watkins L.R. Central proinflammatory cytokines and pain enhancement. Neurosignals 2005, 14(4):166-174.
211. Wieseler F.J., Maier S.F., Watkins L.R. Immune-to-brain communication dynamically modulates pain: physiological and pathological consequences. Brain Behav Immun 2005, 19(2):104-111.
212. Wieseler F.J., Maier S.F., Watkins L.R. Glial activation and pathological pain. Neurochem Int 2004, 45(2-3):389-395.
213. Milligan E.D., Sloane E.M., Langer S.J., et al. Controlling neuropathic pain by adeno-associated virus driven production of the anti-inflammatory cytokine, interleukin-10. Mol Pain 2005, 25:1(1):9.
214. Watkins L.R., Hutchinson M.R., Johnson I.N., Maier S.F. Glia: novel counter-regulators or opioid analgesia. Trends Neurosci 2005, 28(12):661-669.
215. Boswell M.V., Rosenberg S.K., Chelimsky T.C. Neuropathic pain: mechanisms and management. Pain Management 1996, CRC Press, Boca Raton, FL, [chapter 6]. R. Weiner (Ed.).
216. Krause S.J., Backonja M.-M. Development of a neuropathic pain questionnaire. Clin J Pain 2003, 19(5):306-314.
217. Longmire D.R. The medical pain history. Pain Digest 1991, 1(1):29-34.
218. Lindberger M., Schroder H.D., Schultzberg M., et al. Nerve fiber studies in skin biopsies in peripheral neuropathies: immunohistochemical analysis of neuropeptides in diabetes mellitus. J Neurol Sci 1989, 93(2-3):289-296.
219. Wallengren J., Badendick K., Sundler F., et al. Innervation of the skin of the forearm in diabetic patients: relation to nerve function. Acta Derm Venereol 1995, 75(1):37-42.
220. Levy D.M., Terenghi G., Gu X.-H., et al. Immunohistochemical measurements of nerves and neuropeptides in diabetic skin: relationship to tests of neurological function. Diabetologia 1992, 35(9):889-897.
221. Galer B.S., Jensen M.P. Development and preliminary validation of a pain measure specific to neuropathic pain: the neuropathic pain scale. Neurology 1997, 48(2):332-338.
222. Leak W.D. Radiological assessment of the pain patient. Pain Digest 1992, 1(3):218-224.
223. Longmire D.R. Electrodiagnostic studies in the assessment of painful disorders. Pain Digest 1993, 1:2-16.
224. Longmire D.R., Stanton-Hicks M.d'A., Ranieri T.A., Woodley W.E., Leak W.D. Laboratory methods used in the diagnosis of sudomotor dysfunction and complex regional pain syndromes: a critical review. Pain Digest 1996, 6:21-29.
225. Longmire D.R., Parris W.C.V. Selective tissue conductance in the assessment of sympathetically mediated pain. Contemporary Issues in Chronic Pain 1991, 147-160. Kluwer Academic Press, Boston, [chapter 10]. W.C.V. Parris (Ed.).
226. Longmire D.R., Woodley W.E. Clinical neurophysiology of pain-related sympathetic sudomotor dysfunction. Tutorial 11. Pain Digest 1993, 3:202-209.
227. McCarberg B., Barkin R.L., Zaleon C. The management of neuropathic pain with a focus upon older adults. Am J Ther 2012, 19(3):211-227.
228. Arner S., Meyerson B.A. Lack of analgesic effect of opioids on neuropathic and idiopathic forms of pain. Pain 1988, 33(1):11-23.
229. Dellemijn P. Are opioids effective in relieving neuropathic painα. Pain 1999, 80(3):453-462.
230. Katz W.A., Barkin R.L. Dilemmas in chronic/persistent pain management. Dis Mon 2010, 56(4):233-250.
231. Barkin R.L. Extended-release Tramadol (ULTRAM ER): a pharmacotherapeutic, pharmacokinetic, and pharmacodynamic focus on effectiveness and safety in patients with chronic/persistent pain. Am J Ther 2008, 15(2):157-166.
232. Gibofsky A., Barkin R.L. Chronic pain of osteoarthritis: considerations for selecting an extended-release opioid analgesic. Am J Ther 2008, 15(3):241-255.
233. Hegarty A., Portenoy R.K. Pharmacotherapy of neuropathic pain. Semin Neurol 1994, 14(3):213-224.
234. McQuay H.J., Tramer M., Nye B.A., Carroll D., Wiffen P.J., Moore R.A. A systematic review of antidepressants in neuropathic pain. Pain 1996, 68(2-3):217-227.
235. Swerdlow M. Anticonvulsant drugs and chronic pain. Clin Neuropharmacol 1984, 7(1):51-82.
236. Barkin R.L. Tapentadol: a pharmacotherapeutic-focused brief review. Pain Med Netw 2009, 24(8):11. http://www.factsandcomparisons.com.
237. Lexi-Comp, Inc. (Lexi-Drugs™); 2013.
238. Leikin J.B., Paloucek F.P. Poisoning and Toxicology Handbook 2008, Lexi-Comp, Inc., Hudson, OH. 4th ed.
239. Barkin R.L., Sj Barkin, Irving G.A., Gordon A. Management of chronic noncancer pain in depressed patients. Postgrad Med 2011, 123(5):143-154.
240. Castillo J., Curley J., Hotz J., et al. Glucocorticoids prolong rat sciatic nerve blockade in vivo from bupivacaine microspheres. Anesthesiology 1996, 85(5):1157-1166.
241. Devor M., Govrin-Lippmann R., Raber P. Corticosteroids suppress ectopic neural discharge originating in experimental neuromas. Pain 1985, 22(2):127-137.
242. + channels by antidepressant drugs. J Pharmacol Exp Ther 1998, 284(1):208-214.
243. Yaksh T.L. Direct evidence that spinal serotonin and noradrenaline terminals mediate the spinal antinociceptive effects of morphine in the periaqueductal gray. Brain Res 1979, 160(1):180-185.
244. Alhaider A.A., Lei S.Z., Wilcox G.L. Spinal 5-HT3 receptor-mediated antinociception: possible release of GABA. J Neurosci 1991, 11(7):1881-1888.
245. Yaksh T.L., Malmberg A.B. Central pharmacology of nociceptive transmission. Textbook of Pain 1994, 165-200. Churchill Livingstone, Edinburgh. 3rd ed. P.D. Wall, R. Melzack (Eds.).
246. Eisenach J.C., Gebhart G.F. Intrathecal amitriptyline acts as an N-methyl-d-aspartate receptor antagonist in the presence of inflammatory hyperalgesia in rats. Anesthesiology 1995, 83(5):1046-1054.
247. Kim K., Mishina M., Kokubo R., et al. Ketamine for acute neuropathic pain in patients with spinal cord injury. J Clin Neurosci 2013, 20(6):804-807.
248. Barkin R.L., Barkin S.J., Barkin D.S. Perception, assessment, treatment, and management of pain in the elderly. Clin Geriatr Med 2005, 21(3):465-490.
249. Vallejo R., Barkin R.L., Wang V.C. Pharmacology of opioids in the treatment of chronic pain syndromes. Pain Physician 2001, 14(4):E343-E360.
250. Bradley R.H., Barkin R.L., Jerome J., et al. Efficacy of venlafaxine for the long term treatment of chronic pain with associated major depressive disorder. Am J Ther 2003, 10(5):318-323.
251. Leo R.J., Barkin R.L. Antidepressants use in chronic pain management: is there evidence of a role for duloxetineα. Prim Care Companion J Clin Psychiatry 2003, 5(3):118-123.
252. Huff J.P., Barkin R.L., Lagattuta F.P. A primary care clinician's and consultant's guide to medicating for pain and anxiety associated with outpatient procedures. Am J Ther 1994, 1(3):186-190.
253. North R.B., Kidd D.H., Zahurak M., James C.S., Long D.M. Spinal cord stimulation for chronic, intractable pain: experience over two decades. Neurosurgery 1993, 32(3):383-394.
254. Kemler M.A., Barendse G.A.M., van Kleef M., et al. Spinal cord stimulation in patients with chronic reflex sympathetic dystrophy. N Engl J Med 2000, 343(9):618-624.
255. Iacono R.P., Guthkelch A.N., Boswell M.V. Dorsal root entry zone stimulation for deafferentation pain. Stereotact Funct Neurosurg 1992, 59(1-4):56-61.
256. Ahmed H.E., Craig W.F., White P.F., et al. Percutaneous electrical nerve stimulation: an alternative to antiviral drugs for acute herpes zoster. Anesth Analg 1998, 87(4):1-4.
257. Ghoname E.A., White P.F., Ahmed H.E., Hamza A., Craig W.F., Noe C.E. Percutaneous electrical nerve stimulation: an alternative to TENS in the management of sciatica. Pain 1999, 83(2):193-199.
258. Hamza M.A., White P.F., Craig W.F., et al. Percutaneous electrical nerve stimulation: a novel analgesic therapy for diabetic neuropathic pain. Diabetes Care 2000, 23(3):365-370.
259. Goli V. A mechanistic approach to the treatment of neuropathic pain: Symposium, Dannemiller Foundation. 2002.
260. Gracely R.H., Lynch S.A., Bennett G.J. Painful neuropathy: altered central processing, maintained dynamically by peripheral input. Pain 1992, 51(2):175-194.
261. Price D.D., Mao J., Mayer D.J. Central neural mechanisms of normal and abnormal pain states. Pharmacological Approaches to the Treatment of Chronic Pain: New Concepts and Critical Issues. Progress in Pain Research and Management 1994, 1:61-84. IASP Press, Seattle.
262. Kovelowski C.J., Ossipov M.H., Sun H., Malan T.P., Porecca F. Supraspinal cholecystokinin may drive tonic descending facilitation mechanisms to maintain neuropathic pain in the rat. Pain 2000, 87(3):265-273.
263. Vanderah T.W., Gardell L.R., Burgess S.H., et al. Dynorphin promotes abnormal pain and spinal opioid antinociceptive tolerance. J Neurosci 2000, 20(18):7074-7079.
264. Caudle R.M., Mannes A.J. Dynorphin, friend or foeα. Pain 2000, 87(3):235-239.
265. Barkin R.L., Barkin S.J. Reexamining the elderly patient's presentation with depression. Prim Care Companion J Clin Psychiatry 2008, 10(5):415-416.
266. Hart R.G., Easton J.D. Carbamazepine and hematological monitoring. Ann Neurol 1982, 11(3):309-312.
267. Sobotka J.L., Alexander B., Cook B.L. A review of carbamazepine's hematologic reactions and monitoring recommendations. Ann Pharmacother 1990, 24(12):1214-1219.
268. Tohen M., Castillo J., Baldessarin R.J., Zarate C., Kando J.C. Blood dyscrasias with carbamazepine and valproate: a pharmacoepidemiological study of 2,228 patients at risk. Am J Psychiatry 1995, 152(3):413-418.
269. Blom S. Trigeminal neuralgia: its treatment with a new anticonvulsant drug (G-32883). Lancet 1962, 1(7234):839-840.
270. Brodie M.J., Dichter M.A. Antiepileptic drugs. N Engl J Med 1996, 334(3):168-175.
271. Matthew N.T., Saper J.R., Silberstein S.D., et al. Migraine prophylaxis with divalproex. Arch Neurol 1995, 52(3):281-286.
272. Raskin P., Donofrio P.D., Rosenthal N.R., et al. Topiramate vs. placebo in painful diabetic neuropathy: analgesic and metabolic effects. Neurology 2004, 63(5):865-873.
273. Taylor C.P., Gee N.S., Su T.Z., et al. A summary of mechanistic hypotheses of gabapentin pharmacology. Epilepsy Res 1998, 29(3):233-249.
274. Jun J.H., Yaksh T.L. The effect of intrathecal gabapentin and 3-isobutyl gamma-aminobutyric acid on the hyperalgesia observed after thermal injury in the rat. Anesth Analg 1998, 86(2):348-354.
275. Chapman V., Suzuki R., Chamarette H.L.C., Rygh L.J., Dickenson A.H. Effects of systemic carbamazepine and gabapentin on spinal neuronal responses in spinal nerve ligated rats. Pain 1998, 75(2-3):261-272.
276. Abdi S., Lee D.H., Chung J.M. The anti-allodynic effects of amitriptyline, gabapentin, and lidocaine in a rat model of neuropathic pain. Anesth Analg 1998, 87(6):1360-1366.
277. Shimoyama N., Shimoyama M., Davis A.M., Inturrisi C.E., Elliott K.J. Spinal gabapentin is antinociceptive in the rat formalin test. Neurosci Lett 1997, 222(1):65-67.
278. Shimoyama M., Shimoyama N., Inturrisi C.E., Elliott K.J. Gabapentin enhances the antinociceptive effects of spinal morphine in the rat tail-flick test. Pain 1997, 72(3):375-382.
279. Backonja M.M., Beydoun A., Edwards K.R., et al. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus. A randomized controlled trial. J Am Med Assoc 1998, 280(21):1831-1836.
280. Morello C.M., Leckband S.G., Stoner C.P., Moorhouse D.F., Sahagian G.A. Randomized double-blind study comparing the efficacy of gabapentin with amitriptyline on diabetic peripheral neuropathy. Arch Intern Med 1999, 159(16):1931-1937.
281. Mattia C., Coluzzi F. Tramadol: focus on musculoskeletal and neuropathic pain. Minerva Anestesiol 2005, 71(10):565-584.
282. Sindrup S.H., Jensen T.S. Efficacy of pharmacological treatments of neuropathic pain: an update and effect related to mechanism of drug action. Pain 1999, 83(3):389-400.
283. Sindrup S.H., Jensen T.S. Pharmacological treatment of pain in polyneuropathy. Neurology 2000, 55(7):915-920.
284. Bruckental P., Barkin R.L. Options for treating postherpetic neuralgia in the medically complicated patient. Ther Clin Risk Manage 2013, 2013(9):329-340.
285. Rowbotham M., Harden N., Stacey B., Bernstein P., Magnus-Miller L. Gabapentin for the treatment of postherpetic neuralgia. A randomized controlled trial. J Am Med Assoc 1998, 280(21):1837-1842.
286. Beydoun A., Uthman B.M., Sackellares J.C. Gabapentin: pharmacokinetics, efficacy, and safety. Clin Neuropharmacol 1995, 18(6):469-481.
287. Zareba G. Pregabalin: a new agent for the treatment of neuropathic pain. Drugs Today (Barc) 2005, 41(8):509-516.
288. Freynhagen R., Stojek K., Griesing T., et al. Efficacy of pregabalin in neuropathic pain evaluated in a 12-week, randomised, double-blind, multicenter, placebo-controlled trial of flexible- and fixed-dose regimens. Pain 2005, 115(3):254-263.
289. Lesser H., Sharma U., LaMoreaux L., Poole R.M. Pregabalin relieves symptoms of painful diabetic neuropathy: a randomized controlled trial. Neurology 2004, 63(11):2104-2110.
290. Richter R.W., Portenoy R., Sharma U., et al. Relief of painful diabetic peripheral neuropathy with pregabalin: a randomized, placebo-controlled trial. J Pain 2005, 6(4):253-260.
291. Frampton J.E., Scott L.J. Pregabalin: in the treatment of painful diabetic peripheral neuropathy. Drugs 2004, 64(24):2813-2820.
292. Rosenstock J., Tuchman M., LaMoreaux L., Sharma U. Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo controlled trial. Pain 2004, 110(3):628-638.
293. Hadj Tahar A. Pregabalin for peripheral neuropathic pain. Issues Emerg Health Technol 2005, 67:1-4.
294. Max M. Antidepressants as analgesics. Pharmacological Approaches to the Treatment of Chronic Pain: New Concepts and Critical Issues. Progress in Pain Research and Management 1994, 1:229-246. IASP Press, Seattle.
295. Onghena P., van Houdenhove B. Antidepressant-induced analgesia in chronic non-malignant pain: a meta-analysis of 39 placebo controlled studies. Pain 1992, 49(2):205-220.
296. Glassman A., Roose S., Bigger J. The safety of tricyclic antidepressants in cardiac patients. Risk-benefit reconsidered. J Am Med Assoc 1993, 269(20):2673-2677.
297. Drugs Used in Mood Disorders. AMA Drug Evaluations Annual 1993, 277-306. American Medical Association, American Medical Association, Chicago.
298. Sindrup S.H., Gram L.F., Brosen K., Eshj O., Morgensen E.F. The selective serotonin reuptake inhibitor paroxetine is effective in the treatment of diabetic neuropathy symptoms. Pain 1990, 42(2):135-144.
299. Rani P.U., Naidu M.U.R., Prasad V.B.N., Rao T.R.K., Shobha J.C. An evaluation of antidepressants in rheumatic pain conditions. Anesth Analg 1996, 83(2):371-375.
300. Schreiber S., Backer M.M., Pick C.G. The antinociceptive effect of venlafaxine in mice is mediated through opioid and adrenergic mechanisms. Neurosci Lett 1999, 273(2):85-88.
301. Galer B.S. Neuropathic pain of peripheral origin: advances in pharmacologic treatment. Neurology 1995, 45(suppl 9):S17-S25.
302. Rowbotham M.C., Goli V., Kunz N.R., Lei D. Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo controlled study. Pain 2004, 110(3):697-706.
303. Wernicke J.F., Gahimer J., Yalcin I., et al. Safety and adverse event profile of duloxetine. Expert Opin Drug Saf 2005, 4(6):987-993.
304. Kirwin J.L., Goren J.L. Duloxetine: a dual serotonin-norepinephrine reuptake inhibitor for treatment of major depressive disorder. Pharmacotherapy 2005, 25(3):396-410.
305. Maizels M., McCarberg B. Antidepressants and antiepileptic drugs for chronic non-cancer pain. Am Fam Physician 2005, 71(3):483-490.
306. Med Lett Drugs Ther 2005, 47(1215-1216):67-68. Duloxetine (Cymbalta) for diabetic neuropathic pain.
307. Raskin J., Pritchett Y.L., Wang F., et al. A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain. Pain Med 2005, 6(5):346-356.
308. Goldstein D.J., Lu Y., Detke M.J., et al. Duloxetine vs. placebo in patients with painful diabetic neuropathy. Pain 2005, 116(1-2):109-118.
309. Arnold L.M., Lu Y., Crofford L.J., et al. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis Rheum 2004, 50(9):2974-2984.
310. Offenbaecher M., Ackenheil M. Current trends in neuropathic pain treatments with special reference to fibromyalgia. CNS Spectr 2005, 10(4):285-297.
311. Sindrup S., Otto M., Finnerup N., Jensen T. Antidepressants in the treatment of neuropathic pain. Basic Clin Pharm Toxicol 2005, 96(6):399-409.
312. Barkin R.L., Barkin S.J., Barkin D.S. Pharmacotherapeutic management of pain with a focus directed at the geriatric patient. Rheum Dis Clin North Am 2007, 33(1):1-31.
313. Barkin R.L., Barkin S. The role venlafaxine and duloxetine in the treatment of depression with decremental changes in somatic symptoms of pain, chronic pain, and the pharmacokinetics and clinical considerations of duloxetine pharmacotherapy. Am J Ther 2005, 12(5):431-438.
314. Grond S., Sablotzki A. Clinical pharmacology of tramadol. Clin Pharmacokinet 2004, 43(13):879-923.
315. Desmeules J.A. The tramadol option. Eur J Pain 2000, 4(suppl A):15-21.
316. Dworkin R.H., Backonja M., Rowbotham M.C., et al. Advances in neuropathic pain. Arch Neurol 2003, 60(11):1524-1534.
317. Stacey B.R. Management of peripheral neuropathic pain. Am J Phys Med Rehabil 2005, 84(suppl 3):S4-16.
318. Marchettini P., Teloni L., Formaglio F., Lacerenza M. Pain in diabetic neuropathy case study: whole patient management. Eur J Neurol 2004, 11(Suppl 1):12-21.
319. Sindrup S.H., Andersen G., Madsen C., et al. Tramadol relieves pain and allodynia in polyneuropathy: a randomised, double-blind, controlled trial. Pain 1999, 83(1):85-90.
320. Waikakul S., Waikakul W., Penkitti P., et al. Comparison of analgesics for pain after brachial plexus injury: tramadol vs. paracetamol with codeine. Pain Clinic 1998, 11:119-124.
321. Harati Y., Gooch C., Sweenson M., et al. Double-blind randomized trial of tramadol for the treatment of the pain of diabetic neuropathy. Neurology 1998, 50(6):1842-1846.
322. Duhmke R.M., Cornblath D.D., Hollingshead J.R. Tramadol for neuropathic pain. Cochrane Database Syst Rev 2004, 2:CD003726.
323. Cook R.J., Sackett D.L. The number needed to treat: a clinically useful measure of treatment effect. Br Med J 1995, 310(6977):452-454.
324. Chabal C., Jacobson L., Mariano A., Chaney E., Britell C.W. The use of oral mexiletine for the treatment of pain after peripheral nerve injury. Anesthesiology 1992, 76(4):513-517.
325. Abram S.E., Yaksh T.L. Systemic lidocaine blocks nerve injury-induced hyperalgesia and nociceptor-driven spinal sensitization in the rat. Anesthesiology 1994, 80(2):383-391.
326. Sotgiu M.L., Lacerenza M., Marchettini P. Effect of systemic lidocaine on dorsal horn neuron hyperactivity following chronic peripheral nerve injury in rats. Somatosens Mot Res 1992, 9(3):227-233.
327. Burchiel K.J., Chabal C. A role for systemic lidocaine challenge in the classification of neuropathic pains. Pain Forum 1995, 4:81-82.
328. Chaplan S.R., Flemming B.W., Shafer S.L., Yaksh T.L. Prolonged alleviation of tactile allodynia by intravenous lidocaine in neuropathic rats. Anesthesiology 1995, 83(4):775-785.
329. Jaffe R.A., Rowe M.A. Subanesthetic concentrations of lidocaine selectively inhibit a nociceptive response in the isolated rat spinal cord. Pain 1995, 60(2):167-174.
330. Galer B.S., Miller K.V., Rowbotham M.C. Response to intravenous lidocaine infusion differs based on clinical diagnosis and site of nervous system injury. Neurology 1993, 43(6):1233-1235.
331. Saal J.S., Franson R.C., Dobrow R., Saal J.A., White A.H., Goldthwaite N. High levels of inflammatory phospholipase A2 activity in lumbar disc herniations. Spine 1990, 15(7):674-678.
332. Barkin R.L. The pharmacology of topical analgesic. Postgrad Med 2013, 125(4):7-18.
333. Fromm G.H., Terrence C.F., Chattha A.S. Baclofen in the treatment of trigeminal neuralgia: double-blind study and long-term follow-up. Ann Neurol 1984, 15(3):240-244.
334. Caternia M.J., Schumacher M.A., Tominga M., et al. The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature 1997, 389:816-824.
335. Kamel J., Mizoguchi H., Narita M., Tseng L.F. Therapeutic potential of PKC inhibitors in painful diabetic neuropathy. Exp Opin Invest Drugs 2001, 10(9):1653-1664.
336. Haslbeck M. New options in the treatment of various forms of diabetic neuropathy. MMW Fortschr Med 2004, 146(21):47-50.
337. Vinik A.I., Bril V., Kempler P., et al. Treatment of symptomatic diabetic peripheral neuropathy with the protein kinase C beta-inhibitor ruboxistaurin mesylate during a 1-year, randomized, placebo controlled, double-blind clinical trial. Clin Ther 2005, 27(8):1164-1180.
338. Khedr E.M., Kotb H., Kamel N.F., et al. Longlasting antalgic effects of daily sessions of repetitive transcranial magnetic stimulation in central and peripheral neuropathic pain. J Neurol Neurosurg Psychiatry 2005, 76(6):833-838.
339. Finnerup N.B., Otto M., McQuay H.J., et al. Algorithm for neuropathic pain treatment: an evidence based proposal. Pain 2005, 118(3):289-305.
340. Foley K.M. Pain syndromes in patients with cancer. Med Clin North Am 1987, 71(2):169-184.
341. Galer B.S., Rowbotham M.C., Perander J., Friedman E. Topical lidocaine patch relieves posttherpetic neuralgia more effectrively than a vehicle topical patch: results of an enriched enrollment study. Pain 1999, 80(3):533-538.
342. Longmire D.R. The physical examination: methods and application in the clinical evaluation of pain. Pain Digest 1991, 1(2):136-143.